[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608130":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":129,"collaborators":20,"id":131,"slug":20,"hasResults":132,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":20,"eligibilityCriteria":135,"healthyVolunteers":132,"sex":136,"minAge":137,"maxAge":20,"enrollmentInfo":138,"targetDuration":20,"studyType":141,"phases":142,"briefSummary":144,"conditions":145,"keywords":150,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":171},{"fullName":5,"class":6},"SEED Therapeutics, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation","EXPERIMENTAL","ST-01156, administered orally once daily for 5 consecutive days followed by 2 days without study drug administration every 7 days",[13],"Drug: ST-01156",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","ST-01156","ST-01156 is an orally administered degrader of RBM39, a protein frequently upregulated in cancer",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Dr. Eric Rowinsky Chief Medical Officer","CONTACT","(908) 883-0647","erowinsky@oncodrugs.com",[28,49,65,82,95,111],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"The City of Hope National Medical Center","RECRUITING","Duarte","California","91010","United States",{"type":36,"coordinates":37},"Point",[38,39],-117.97729,34.13945,{"lat":39,"lon":38},[42,46],{"name":43,"role":24,"phone":44,"phoneExt":20,"email":45},"Kathryn Zurcher","626-218-3029","kzurcher@coh.org",{"name":47,"role":48,"phone":20,"phoneExt":20,"email":20},"Daneng Li","PRINCIPAL_INVESTIGATOR",{"facility":50,"status":30,"city":51,"state":32,"zip":52,"country":34,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"Hoag Memorial Hospital","Newport Beach","92263",{"type":36,"coordinates":54},[55,56],-117.92895,33.61891,{"lat":56,"lon":55},[59,63],{"name":60,"role":24,"phone":61,"phoneExt":20,"email":62},"Holland Orndorff","949-764-7110","Holland.Orndorff@hoag.org",{"name":64,"role":48,"phone":20,"phoneExt":20,"email":20},"Alain Mita",{"facility":66,"status":30,"city":67,"state":68,"zip":69,"country":34,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Mass General Brigham Cancer Institute","Boston","Massachusetts","02114",{"type":36,"coordinates":71},[72,73],-71.05977,42.35843,{"lat":73,"lon":72},[76,80],{"name":77,"role":24,"phone":78,"phoneExt":20,"email":79},"Kristina Goodwin","617-643-6256","kgoodwin@mgh.harvard.edu",{"name":81,"role":48,"phone":20,"phoneExt":20,"email":20},"Gregory Cote",{"facility":83,"status":30,"city":67,"state":68,"zip":84,"country":34,"cosmosGeoPoint":85,"geoPoint":87,"contacts":88},"Dana Farber Cancer Institute","02215",{"type":36,"coordinates":86},[72,73],{"lat":73,"lon":72},[89,93],{"name":90,"role":24,"phone":91,"phoneExt":20,"email":92},"Suzanne George","877-338-7425","Suzanne_George@dfci.harvard.edu",{"name":94,"role":48,"phone":20,"phoneExt":20,"email":20},"Suzanne George, MD",{"facility":96,"status":30,"city":97,"state":97,"zip":98,"country":34,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Memorial Sloan Kettering Cancer Center","New York","10065",{"type":36,"coordinates":100},[101,102],-74.00597,40.71427,{"lat":102,"lon":101},[105,109],{"name":106,"role":24,"phone":107,"phoneExt":20,"email":108},"Pri Wartanian","210-685-2159","wartant@mskcc.org",{"name":110,"role":48,"phone":20,"phoneExt":20,"email":20},"Robert Maki",{"facility":112,"status":30,"city":113,"state":114,"zip":115,"country":34,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"The University of Texas MD Anderson Cancer Center","Houston","Texas","77030",{"type":36,"coordinates":117},[118,119],-95.36327,29.76328,{"lat":119,"lon":118},[122,127],{"name":123,"role":24,"phone":124,"phoneExt":125,"email":126},"Kofi Effa Ababio","346-725-3989","53989","KEAbabio@mdanderson.org",{"name":128,"role":48,"phone":20,"phoneExt":20,"email":20},"Jordi Rodon Ahnert",{"type":130,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100608130",false,"NCT07197554","A Phase 1\u002F1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies","Inclusion Criteria:\n\n* Age ≥ 18 years on the day of signing the consent form, except for adolescents with Ewing Sarcoma or other malignancies for which there is a biological rationale to support participation, in which case the participant is ≥ 16 years old.\n* Has a metastatic or locally advanced and unresectable solid tumor.\n* Has at least 1 measurable lesion or evaluable disease per RECIST v1.1.\n* Has an ECOG performance status ≤ 2 at screening.\n* Has adequate organ function as defined in the protocol.\n\nExclusion Criteria:\n\n* Has received prior radiotherapy within 2 weeks of treatment.\n* Has known active CNS metastases and\u002For carcinomatous meningitis. Participants with previously treated brain metastases may participate, provided they are radiologically stable\n* Has received treatment with any local or systemic anticancer therapy or investigational anticancer agent within 14 days or 5 half-lives, whichever is shorter.\n* Had major surgery within 28 days before study therapy administration\n* Has toxicities from previous anticancer therapies that have not resolved to baseline levels, with the exception of alopecia and peripheral neuropathy.\n* Has previously received a RBM39 inhibitor\u002Fdegrader.","ALL","16 Years",{"count":139,"type":140},171,"ESTIMATED","INTERVENTIONAL",[143],"PHASE1","A Phase 1\u002F1B Study of ST-01156 in Patients with Advanced Solid Malignancies",[146,147,148,149],"Advanced Solid Tumors","Ewing Sarcoma","Hepatocellular Carcinoma (HCC)","Biliary Tract Cancer (BTC)",[151,152,153,154,155,156,157,158,159,160,161],"cancer","solid tumors","RBM39","RBM39 degrader","metastatic solid malignancies","Ewing sarcoma","Hepatocellular carcinoma","HCC","Biliary tract carcinoma","endometrial carcinoma","Adolescents","2026-05-30",{"date":164,"type":165},"2026-06-02","ACTUAL",{"date":167,"type":165},"2025-12-01",{"date":169,"type":140},"2029-12-31",{"name":5,"class":6},6]